The one law of CEO pay pack­ages: They keep get­ting big­ger.

Yes­ter­day, we pub­lished the first in­stall­ment of End­points News’ an­nu­al bio­phar­ma com­pen­sa­tion project. Fol­low­ing our analy­sis of the in­dus­try’s top-paid CEOs, we’ll break down what top sci­ence and med­ical lead­ers make, dig in­to me­di­an em­ploy­ee pay (and how that com­pares to CEOs) and un­veil the rich­est gold­en para­chutes, as well as an ex­am­i­na­tion of ex­ec­u­tive perks. You’ll be able to find all of that re­port­ing here.

To­day at 12:30 p.m. ET, I’m join­ing our Ex­ec­u­tive Ed­i­tor Drew Arm­strong on Post-Hoc Live to dig in­to about the eye-pop­ping num­bers in some CEO pay pack­ages and the be­hind-the-scenes of how this re­port­ing comes to­geth­er.

Putting all this da­ta to­geth­er in one place does more than just re­veal bio­phar­ma’s pay­roll. It al­so rais­es ques­tions about how these com­pa­nies think about lead­er­ship and pri­or­i­tize their bud­gets. Are there oth­er ways bio­phar­mas could spend some of the mil­lions go­ing to­ward ex­ec­u­tive pack­ages? Do CEOs ac­tu­al­ly get paid com­men­su­rate with their com­pa­ny’s suc­cess? How does pay af­fect in­cen­tives and glob­al com­pe­ti­tion?